Cargando…

1037. Efficacy of Germinants and Omadacycline for Preventing Clostridioides difficile Relapse in a Murine Model

BACKGROUND: Clostridioides difficile is labeled one of five urgent pathogens by the CDC. The urgency is related to the high burden of disease, limited effective antimicrobials, and recurrent C. difficile infections (rCDI) from residual spores (Fig. 1). Impervious to antibiotics, C. difficile spores...

Descripción completa

Detalles Bibliográficos
Autores principales:	Budi, Noah, Godfrey, Jared, Shukla, Sanjay, Safdar, Nasia, Rose, Warren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644223/ http://dx.doi.org/10.1093/ofid/ofab466.1231

Ejemplares similares

Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah D, et al.
Publicado: (2022)

Treatment issues in recurrent Clostridioides difficile infections and the possible role of germinants
por: Budi, Noah, et al.
Publicado: (2020)

Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence
por: Garey, Kevin W., et al.
Publicado: (2022)

661. In vitro Activity of Omadacycline and Comparator Antibiotics against Clostridioides difficile
por: Skinner, Andrew M, et al.
Publicado: (2022)

The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
por: Seekatz, Anna Maria, et al.
Publicado: (2022)

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020)

Clinical Characteristics and Fecal Microbiome in Recurrent Versus Nonrecurrent Clostridioides difficile Infection
por: Lanjewar, Swapnil, et al.
Publicado: (2021)

In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden
por: Camporeale, Angela, et al.
Publicado: (2021)

277. A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
por: Jo, Jinhee, et al.
Publicado: (2023)

Validating agent-based simulation model of hospital-associated Clostridioides difficile infection using primary hospital data
por: Scaria, Elizabeth, et al.
Publicado: (2023)

Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset Clostridioides difficile Infection
por: Barker, Anna K., et al.
Publicado: (2020)

1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
por: Rodriguez, Mauricio, et al.
Publicado: (2020)

Association of Visitor Contact Precautions With Estimated Hospital-Onset Clostridioides difficile Infection Rates in Acute Care Hospitals
por: Scaria, Elizabeth, et al.
Publicado: (2021)

Clostridioides difficile Biology: Sporulation, Germination, and Corresponding Therapies for C. difficile Infection
por: Zhu, Duolong, et al.
Publicado: (2018)

Negative interactions determine Clostridioides difficile growth in synthetic human gut communities
por: Hromada, Susan, et al.
Publicado: (2021)

Neighborhood disadvantage and 30-day readmission risk following Clostridioides difficile infection hospitalization
por: Scaria, Elizabeth, et al.
Publicado: (2020)

2377. Social Determinants Impact Readmission Following Clostridioides difficile-Related Index Hospital Stay in Medicare Patients
por: Scaria, Elizabeth, et al.
Publicado: (2019)

1208. Omadacycline In Vitro Activity Against Bacillus Anthracis
por: Serio, Alisa W, et al.
Publicado: (2021)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

2418. Determining the Impact of Visitor Contact Precautions on Hospital-Onset Clostridioides difficile Infection Rates: An Agent-Based Simulation Modeling Approach
por: Alagoz, Oguzhan, et al.
Publicado: (2019)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
por: Gagelmann, Nico, et al.
Publicado: (2023)

71. Diagnostic Stewardship of Clostridioides difficile Testing
por: Qamar, Zahra, et al.
Publicado: (2021)

Convenient Protocol for Production and Purification of Clostridioides difficile Spores for Germination Studies
por: Weldy, Melissa, et al.
Publicado: (2020)

2423. Cost-effectiveness of core and emerging infection control interventions to reduce hospital-onset Clostridioides difficile infection: An agent-based simulation modeling approach
por: Alagoz, Oguzhan, et al.
Publicado: (2019)

Decreasing ICU-associated Clostridioides difficile infection through fluoroquinolone restriction, the FIRST trial: a study protocol
por: Safdar, Nasia, et al.
Publicado: (2021)

Assessing the Feasibility of Employing a Combination of a Bacteriophage-Derived Endolysin and Spore Germinants to Treat Relapsing Clostridioides difficile Infection
por: Alyahya, Khalid, et al.
Publicado: (2023)

Differential effects of ‘resurrecting' Csp pseudoproteases during Clostridioides difficile spore germination
por: Donnelly, M. Lauren, et al.
Publicado: (2020)

697. Outcomes of Tigecycline Use for Clostridioides difficile Infection: A Case Series of 28 Patients
por: Phillips, Emma C, et al.
Publicado: (2021)

A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
por: Shelby, Rita D., et al.
Publicado: (2020)

792. Evaluation of Persistent Diarrhea and Recurrence Following Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
por: Boton, Noah, et al.
Publicado: (2020)

The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favoring the onset of Clostridioides difficile infection and relapses
por: Bassotti, Gabrio, et al.
Publicado: (2020)

1197. Inhibitory Effect of Ursodeoxycholic Acid on Clostridioides difficile Growth
por: Alnezary, Faris, et al.
Publicado: (2020)

783. Clostridioides difficile Infection among Maintenance Hemodialysis Patients
por: Radhakrishnan, Parvathi, et al.
Publicado: (2020)

755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
por: Al-Bahou, Amanda, et al.
Publicado: (2021)

782. Clostridioides difficile environmental contamination in hospitalized patients with diarrhea: a pilot study
por: Warren, Bobby G, et al.
Publicado: (2020)

784. A Novel Method to Assess Virulence of Clostridioides difficile: Focus on C. difficile Ribotype 106
por: Almutairi, Masaad, et al.
Publicado: (2020)

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES
por: Harrison, C., et al.
Publicado: (2022)

Single-spore germination analyses reveal that calcium released during Clostridioides difficile germination functions in a feedforward loop
por: Ribis, John W., et al.
Publicado: (2023)

Epidemiology and outcomes of Clostridium difficile infection among hospitalised patients: results of a multicentre retrospective study in South Africa
por: Legenza, Laurel, et al.
Publicado: (2018)

1416. Assessing the potential for interspecies transmission of Clostridioides difficile on dairy farms
por: Redding, Laurel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s0830kpcj68jvkiuk7q7had8pj